Neurocrine Initiates Phase 2 Trial of Crinecerfont in Children Under 4 with Classic CAH
SAN DIEGO, July 1, 2026 Neurocrine Biosciences announced the initiation of a Phase 2 clinical trial evaluating crinecerfont (CRENESSITY®)...
congenital adrenal hyperplasia
Advertisement
Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
Neurocrine Reports Two-Year CRENESSITY Data Showing Improved Growth in Pediatric CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
Neurocrine Shows CRENESSITY Sustains CAH Control Data
San Diego, USA – April 22, 2026 In a major advancement for endocrine disorder management, Neurocrine Biosciences has unveiled...
Advertisement
